facebook  linkedin xpix

Diary Dates
Save the date for important iCMLf meetings and programs
calendar

Become a member

Become an iCMLf member - help shape our future
member-button

Please donate

Support our activities
by donating
Donate here

Supporters

We thank all our supporters and partners

supporter-lay2

If you are not a member, please click on "Register". If you have forgotten your password, please click on "Forgot login?" below.

iCMLf Expert Opinions

This section provides you with a selection of expert opinions from leaders in the field. 

You will find interviews with CML experts providing their personal perspectives on highlights from scientific meetings and latest scientific advancements as well as keynote presentations from iCMLf prize winners. The topics featured cover a broad range of issues from CML science to clinical practice.   

 

 

Keynote presentations from the recipients of the 2017 iCMLf Prizes

At the 19th Annual John Goldman Conference on CML in Estoril the iCMLf Directors awarded the Foundation’s 2017 prize medals. This was followed by keynote presentations from the three prize winners. You can view web streams of the keynote presentations here.

iCMLf Prize recipients 2017

 

  • 2017 Goldman Prize: Professor Timothy Hughes
  • 2017 iCMLf Prize: Professor Jerald Radich
  • 2017 Rowley Prize: Professor Tessa Holyoake 

At Tessa’s request, her keynote was presented by Mhairi Copland, Professor of Translational Haematology at the Paul O’ Gorman Leukemia Research Center at the University of Glasgow.

 

Read more ...

Highlights from the John Goldman Conference on CML 2017:
CML experts give their personal perspectives

 

        

 

Perspectives on biology and clinical aspects 
from Professor Jorge Cortes
MD Anderson Cancer Center
University of Texas, Houston (USA)

  • Leukemic stem cells and microenvironment
  • Biomarkers 
  • Conceptual understanding of treatment-free remission 
  • Treatment discontinuation with 2nd generation TKI's
  • Update on the new ELN recommendations
  • Patient-reported outcomes
  • New modalities of monitoring patients
  • Long-term outcomes from various clinical studies

 

Read more ...

Highlights from EHA 2017:
2 CML experts give their personal perspectives

 

        

Perspectives on new CML studies from
Professor Timothy Hughes
South Australian Health and Medical Research Institute (SAHMRI), University of Adelaide, Royal Adelaide Hospital, Australia

  • Phase II study on dasatinib in children and adolescents with CML-CP
  • 10-year survival results of the German CML IV Study
  • Year 2 results from the British Destiny Study 
  • Initial results from the Before trial: Bosutinib vs. Imatinib in newly diagnosed CML
  • Update on treatment-free remission studies

 

Read more ...

 

           

Perspectives on CML management from 
Professor Jerry Radich
Fred Hutchinson Cancer Research Center
Seattle, USA

  • Assessment of existing therapies in CML including new data on bosunitib in front-line therapy
  • Emerging new therapies for CML and how they could come into practice
  • Perspectives on treatment discontinuation
  • Challenges of CML management in the emerging economic regions: access to treatment and testing

Read more ...

Highlights from ASH 2016:
3 CML experts give their personal perspectives

This independent educational resource is supported by a grant from Novartis Oncology

 

        

Perspectives on molecular monitoring in CML from 
Associate Professor Susan Branford, PhD
Center for Cancer Biology
SA Pathology, Adelaide, Australia

  • Treatment-free remission studies including an update of the EURO-SKI trial
  • New data on optimal timing for monitoring patients after stopping therapy
  • Additional chromosomal abnormalities and their impact on prognosis
  • Next generation sequencing technologies 

 

Read more ...

 

           

Perspectives from Professor Jorge Cortes, MD

MD Anderson Cancer Center
University of Texas, Houston, USA

  • Different aspects on treatment discontinuation including 2nd treatment discontinuation and QoL assessment
  • Presentation of a new tyrosine kinase inhibitor
  • Generics making it into practice
  • Predictive markers and their impact on patients outcome
  • Considerations for treatment discontinuation in clinical practice including AE management

Read more ...

 

           

Perspectives on QoL assessment in CML patients from Dr Fabio Efficace, PhD 

Fondazione GIMEMA, Rome, Italy

Northwestern University, Feinberg School of Medicine, Chicago, USA

  • Importance of QoL assessment in CML
  • Correlation between QoL and adherence to therapy
  • Update on QoL data from the ENEST trials
  • Overview of measuring instruments to assess QoL and the importance of patient-related QoL measures

 

Read more ...

 

Keynote presentations from the recipients of the 2016 iCMLf Prizes

At the 18th Annual John Goldman Conference on CML in Houston the iCMLf Directors awarded the Foundation’s 2016 prize medals. This was followed by keynote presentations from the three prize winners. You can view web streams of the keynote presentations here.

Collage 2016 Keynotes Prizes

 

 

  • 2016 Rowley Prize: Professor Nora Heisterkamp 
  • 2016 Goldman Prize: Professor Hagop Kantarjian
  • 2016 iCMLf Prize: Associate Professor Susan Branford

Read more ...

Highlights from EHA 2016:
3 CML experts give their personal perspectives

This independent educational resource is supported by a grant from Novartis Oncology

 

        



Perspectives from Prof. Michele Baccarani
Chairman of CML Working Party of European LeukemiaNet,
Founding member of the iCMLf, Università di Bologa, Italy

  • The unmet needs in CML
  • Pathways to treatment free response
  • Next generation sequencing - the impact on future treatment decision making

 

Read more ...

 

           

 


Perspectives from Prof. Francois-Xavier Mahon
University de Bordeaux, France

  • Perspectives on treatment discontinuation
  • Proposed critieria for stopping TKI therapy
  • Highlights of EHA

Read more ...

 

           



Perspectives from PD Dr. Susanne Saußele
Universitätsklinikum Mannheim, Germany

  • Key criteria for treatment discontinuation
  • The impact comorbidity has on TKI decision making
  • Additional chromosomal aberrations - considerations in clinical practice
  • Highlights of EHA

Read more ...

Interview with Dr Johan Richter: Euro-ski trial

Dr. Johan Richter 2


You will also find a podcast interview with Dr Johan Richter on stopping tyrosine kinase inhibitors in a large cohort of European myeloid patients: Results of the euro-ski trial on the EHA Learning Center.

To access the video click here and log-in on the EHA Learning Center platform with your EHA login details or create a free account. 

Perspectives on CML in the emerging economic regions

VEP Garcia Gonzalez                   


Perspectives on CML in the emerging economic regions
Interview with Pat Garcia-Gonzalez CEO of The MAX Foundation and recipient of the 2015 iCMLf ERSAP Prize

  • What has been achieved so far to increase global access to therapy and care to patients?
  • What are the biggest challenges still to be met in the emerging regions?
  • What role do public-private partnerships play to grant access to treatment? 
  • What is the vision for CML management in the emerging regions?

Read more ...

 

Keynote presentations from the recipients of the 2015 iCMLf Prizes

At the 17th Annual John Goldman Conference on CML the iCMLf Directors awarded the Foundation’s prize medals. This was followed by keynote presentations from the three prize winners. You can view web streams of the keynote presentations here as part of the iCMLf Virtual Education Program.

Collage prize winners 2015

 

 

  • 2015 Rowley Prize: Professor Richard Van Etten
  • 2015 John Goldman Prize: Professor Michele Baccarani
  • 2015 ERSAP Prize: Pat Garcia-Gonzalez (The MAX Foundation)

Read more ...

Further Expert opinions

We are pleased to share additional expert opinions on various CML related topics with you here:

 

 

Clinical Care Options (CCO)

Clinical Care Options (CCO) provides interactive online and live CME-certified continuing medical education (CME) programs and proprietary medical education technologies for healthcare professionals. Click here for information on CCO:

Clinical Care Options.ashx

We are pleased to share their recent CML modules below: